ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryo… Read more
ProKidney Corp. (PROK) - Net Assets
Latest net assets as of September 2025: $318.34 Million USD
Based on the latest financial reports, ProKidney Corp. (PROK) has net assets worth $318.34 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($351.61 Million) and total liabilities ($33.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $318.34 Million |
| % of Total Assets | 90.54% |
| Annual Growth Rate | 90.75% |
| 5-Year Change | 3971.75% |
| 10-Year Change | N/A |
| Growth Volatility | 702.92 |
ProKidney Corp. - Net Assets Trend (2019–2024)
This chart illustrates how ProKidney Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ProKidney Corp. (2019–2024)
The table below shows the annual net assets of ProKidney Corp. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $401.64 Million | +2.63% |
| 2023-12-31 | $391.34 Million | -22.50% |
| 2022-12-31 | $504.94 Million | +1775.91% |
| 2021-12-31 | $26.92 Million | +172.88% |
| 2020-12-31 | $9.86 Million | -37.90% |
| 2019-12-31 | $15.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ProKidney Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 112123400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $29.00K | % |
| Other Comprehensive Income | $130.00K | % |
| Other Components | $205.74 Million | % |
| Total Equity | $-994.95 Million | 100.00% |
ProKidney Corp. Competitors by Market Cap
The table below lists competitors of ProKidney Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Jingyuan Environmental Protection Co Ltd
SHG:688096
|
$194.03 Million |
|
Shanxi Guoxin Energy Co Ltd B
SHG:900913
|
$194.06 Million |
|
Nova Technology
TWO:6613
|
$194.15 Million |
|
Shandong Tongda Island New Materials Co Ltd
SHE:300321
|
$194.16 Million |
|
Galaxy Surfactants Limited
NSE:GALAXYSURF
|
$193.98 Million |
|
Elixirr International plc
OTCGREY:ELXXF
|
$193.97 Million |
|
The Rank Group Plc
PINK:RANKF
|
$193.96 Million |
|
Huasi Agricultural Development Co Ltd
SHE:002494
|
$193.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ProKidney Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,103,396,000 to -994,954,000, a change of 108,442,000.
- Net loss of 61,186,000 reduced equity.
- New share issuances of 144,322,000 increased equity.
- Other factors increased equity by 25,306,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-61.19 Million | -6.15% |
| Share Issuances | $144.32 Million | +14.51% |
| Other Changes | $25.31 Million | +2.54% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares ProKidney Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.20 | $2.08 | x |
| 2020-12-31 | $0.05 | $2.08 | x |
| 2021-12-31 | $0.84 | $2.08 | x |
| 2022-12-31 | $-17.82 | $2.08 | x |
| 2023-12-31 | $-17.88 | $2.08 | x |
| 2024-12-31 | $-10.16 | $2.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ProKidney Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -80507.89%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-162.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -501.26% | 0.00% | 0.00x | 1.23x | $-81.20 Million |
| 2020 | -271.18% | 0.00% | 0.00x | 1.69x | $-27.74 Million |
| 2021 | -204.87% | 0.00% | 0.00x | 1.50x | $-57.84 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $1.63 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $74.87 Million |
| 2024 | 0.00% | -80507.89% | 0.00x | 0.00x | $38.31 Million |
Industry Comparison
This section compares ProKidney Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ProKidney Corp. (PROK) | $318.34 Million | -501.26% | 0.10x | $194.01 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |